Interleukin 27 negatively regulates the development of interleukin 17-producing T helper cells during chronic inflammation of the central nervous system

Nature Immunology

Volumn 7, Issue 9, 2006, Pages 937-945

  Stumhofer, Jason S ^a   Laurence, Arian ^b   Wilson, Emma H ^a   Huang, Elaine ^a   Tato, Cristina M ^b   Johnson, Leanne M ^a   Villarino, Alejandro V ^a   Huang, Qiulong ^c   Yoshimura, Akihiko ^d   Sehy, David ^c   Saris, Christiaan J M ^e   O'Shea, John J ^b   Hennighausen, Lothar ^b   Ernst, Matthias ^f   Hunter, Christopher A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^c New Technologies Department   (United States)

^d KYUSHU UNIVERSITY   (Japan)

^e AMGEN INC   (United States)

^f LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 130; INTERLEUKIN 17; INTERLEUKIN 2; INTERLEUKIN 23; INTERLEUKIN 27; INTERLEUKIN 27 RECEPTOR; INTERLEUKIN 6; INTERLEUKIN RECEPTOR; PROTEIN P28; STAT1 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL MATURATION; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC INFLAMMATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG TARGETING; EFFECTOR CELL; HELPER CELL; IMMUNOREGULATION; IN VITRO STUDY; INFLAMMATORY DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; TOXOPLASMA GONDII;

ANIMALS; ANTIGENS, CD4; CENTRAL NERVOUS SYSTEM; ENCEPHALITIS; INTERLEUKIN-17; INTERLEUKIN-6; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; MICE, KNOCKOUT; RECEPTORS, CYTOKINE; STAT1 TRANSCRIPTION FACTOR; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, HELPER-INDUCER; TOXOPLASMA; TOXOPLASMOSIS, CEREBRAL;

EID: 33747593830     PISSN: 15292908     EISSN: 15292916     Source Type: Journal    
DOI: 10.1038/ni1376     Document Type: Article

References (60)

1. H2 cells: Different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7, 145-173 (1989).
2. Aggarwal, S., Ghilardi, N., Xie, M.H., de Sauvage, F.J. & Gurney, A.L. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J. Biol. Chem. 278, 1910-1914 (2003).
3. Langrish, C.L. et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J. Exp. Med. 201, 233-240 (2005).
4. Cua, D.J. et al. Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain. Nature 421, 744-748 (2003).
5. Murphy, C.A. et al. Divergent pro- and antiinflammatory roles for IL-23 and IL-12 in joint autoimmune inflammation. J. Exp. Med. 198, 1951-1957 (2003).
6. Yen, D. et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. J. Clin. Invest. 116, 1310-1316 (2006).
7. Chen, Y. et al. Anti-IL-23 therapy inhibits multiple inflammatory pathways and ameliorates autoimmune encephalomyelitis. J. Clin. Invest. 116, 1317-1326 (2006).
8. Hunter, C.A. New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions. Nat. Rev. Immunol. 5, 521-531 (2005).
9. McKenzie, B.S., Kastelein, R.A. & Cua, D.J. Understanding the IL-23-IL-17 immune pathway. Trends Immunol. 27, 17-23 (2006).
10. Bettelli, E. & Kuchroo, V.K. IL-12- and IL-23-induced T helper cell subsets: Birds of the same feather flock together. J. Exp. Med. 201, 169-171 (2005).
11. Veldhoen, M., Hocking, R.J., Atkins, C.J., Locksley, R.M. & Stockinger, B. TGFβ in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 24, 179-189 (2006).
12. H17 and regulatory T cells. Nature 441, 235-238 (2006).
13. H17 lineage. Nature 441, 231-234 (2006).
14. + T cells. Immunity 16, 779-790 (2002).
15. Pflanz, S. et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. J. Immunol. 172, 2225-2231 (2004).
16. Villarino, A.V. et al. Positive and negative regulation of the IL-27 receptor during lymphoid cell activation. J. Immunol. 174, 7684-7691 (2005).
17. Sprecher, C.A. et al. Cloning and characterization of a novel class I cytokine receptor. Biochem. Biophys. Res. Commun. 246, 82-90 (1998).
18. Chen, Q. et al. Development of Th1-type immune responses requires the type I cytokine receptor TCCR. Nature 407, 916-920 (2000).
19. Heinrich, P.C., Behrmann, I., Muller-Newen, G., Schaper, F. & Graeve, L. Interlukin-6-type cytokine signaling through the gp130/Jak/STAT pathway. Biochem. J. 334, 297-314 (1998).
20. Taga, T. & Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annu. Rev. Immunol. 15, 797-819 (1997).
21. Villarino, A.V. & Hunter, C.A. Biology of recently discovered cytokines: discerning the pro- and anti-inflammatory properties of interleukin-27. Arthritis Res. Ther. 6, 225-233 (2004).
22. Yoshida, H. et al. WSX-1 is required for the initiation of Th1 responses and resistance to L. major infection. Immunity 15, 569-578 (2001).
23. Artis, D. et al. The IL-27 receptor (WSX-1) is an in inhibitor of innate and adaptive elements of type 2 immunity. J. Immunol. 173, 5626-5634 (2004).
24. Hamano, S. et al. WSX-1 is required for resistance to Trypanosoma cruzi infection by regulation of proinflammatory cytokine production. Immunity 19, 657-667 (2003).
25. Rosas, L.E. et al. Interleukin-27R (WSX-1/T-cell cytokine receptor) gene-deficient mice display enhanced resistance to Leishmania donovani infection but develop severe liver immunopathology. Am. J. Pathol. 168, 158-169 (2006).
26. Villarino, A. et al. The IL-27R (WSX-1) is required to suppress T cell hyperactivity during infection. Immunity 19, 645-655 (2003).
27. Villarino, A.V. et al. IL-27 limits IL-2 production during Th1 differentiation. J. Immunol. 176, 237-247 (2006).
28. Li, J., Gran, B., Zhang, G.X., Rostami, A. & Kamoun, M. IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis. J. Neurol. Sci. 232, 3-9 (2005).
29. Sonobe, Y. et al. Production of IL-27 and other IL-12 family cytokines by microglia and their subpopulations. Brain Res. 1040, 202-207 (2005).
30. Wilson, E.H., Wille-Reece, U., Dzierszinski, F. & Hunter, C.A. A critical role for IL-10 in limiting inflammation during toxoplasmic encephalitis. J. Neuroimmunol. 165, 63-74 (2005).
31. Hibbert, L., Pflanz, S., De Waal Malefyt, R. & Kastelein, R.A. IL-27 and IFN-α signal via Stat1 and Stat3 and induce T-Bet and IL-12Rβ2 in naive T cells. J. Interferon Cytokine Res. 23, 513-522 (2003).
32. + T cells. J. Immunol. 173, 3871-3877 (2004).
33. Takeda, A. et al. Cutting edge: Role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. J. Immunol. 170, 4886-4890 (2003).
34. + T cells through Stat1-dependent and -independent mechanisms. Proc. Natl. Acad. Sci. USA 100, 15047-15052 (2003).
35. Egen, J.G., Kuhns, M.S. & Allison, J.P. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat. Immunol. 3, 611-618 (2002).
36. Suzuki, Y., Conley, F.K. & Remington, J.S. Importance of endogenous IFN-γ for prevention of toxoplasmic encephalitis in mice. J. Immunol. 143, 2045-2050 (1989).
37. Owaki, T. et al. IL-27 suppresses CD28-medicated IL-2 production through suppressor of cytokine signaling 3. J. Immunol. 176, 2773-2780 (2006).
38. + T lymphocytes is required to reactivate chronic infection with Toxoplasma gondii. J. Immunol. 149, 175-180 (1992).
39. Israelski, D.M. et al. Treatment with anti-L3T4 (CD4) monoclonal antibody reduces the inflammatory response in toxoplasmic encephalitis. J. Immunol. 142, 954-958 (1989).
40. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat. Immunol. 6, 1123-1132 (2005).
41. Park, H. et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat. Immunol. 6, 1133-1141 (2005).
42. Alexander, W.S. & Hilton, D.J. The role of suppressors of cytokine signaling (SOCS) proteins in regulation of the immune response. Annu. Rev. Immunol. 22, 503-529 (2004).
43. Tebbutt, N.C. et al. Reciprocal regulation of gastrointestinal homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat. Med. 8, 1089-1097 (2002).
44. Croker, B.A. et al. SOCS3 negatively regulates IL-6 signaling in vivo. Nat. Immunol. 4, 540-545 (2003).
45. Chen, Z. et al. Selective regulatory function of Socs3 in the formation of IL-17-secreting T cells. Proc. Natl. Acad. Sci. USA 103, 8137-8142 (2006).
46. Lieberman, L.A., Banica, M., Reiner, S.L. & Hunter, C.A. STAT1 plays a critical role in the regulation of antimicrobial effector mechanisms, but not in the development of Th1-type responses during toxoplasmosis. J. Immunol. 172, 457-463 (2004).
47. Kelly, M.N. et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect. Immun. 73, 617-621 (2005).
48. Happel, K.I. et al. Divergent roles of IL-23 and IL-12 in host defense against Klebsiella pneumoniae. J. Exp. Med. 202, 761-769 (2005).
49. Happel, K.I. et al. Cutting edge: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J. Immunol. 170, 4432-4436 (2003).
50. Watford, W.T. et al. Signaling by IL-12 and IL-23 and the immunoregulatory roles of STAT4. Immunol. Rev. 202, 139-156 (2004).
51. Cho, M.L. et al. STAT3 and NF-κB signal pathway is required for IL-23-mediated IL-17 production in spontaneous arthritis animal model IL-1 receptor antagonist-deficient mice. J. Immunol. 176, 5652-5661 (2006).
52. Hashimoto, K. et al. Respiratory syncytial virus infection in the absence of STAT1 results in airway dysfunction, airway mucus, and augmented IL-17 levels. J. Allergy Clin. Immunol. 116, 550-557 (2005).
53. Bettelli, E. et al. Loss of T-bet, but not STAT1, prevents the development of experimental autoimmune encephalomyelitis. J. Exp. Med. 200, 79-87 (2004).
54. Nguyen, K.B. et al. Interferon α/β-mediated inhibition and promotion of interferon-γ: STAT1 resolves a paradox. Nat. Immunol. 1, 70-76 (2000).
55. Lee, C.K., Smith, E., Gimeno, R., Gertner, R. & Levy, D.E. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFN-γ. J. Immunol. 164, 1286-1292 (2000).
56. Koenders, M.I. et al. Blocking of interleukin-17 during reactivation of experimental arthritis prevents joint inflammation and bone erosion by decreasing RANKL and interleukin-1. Am. J. Pathol. 167, 141-149 (2005).
57. Lubberts, E. et al. Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion. Arthritis Rheum. 50, 650-659 (2004).
58. Hellings, P.W. et al. Interleukin-17 orchestrates the granulocyte influx into airways after allergen inhalation in a mouse model of allergic asthma. Am. J. Respir. Cell Mol. Biol. 28, 42-50 (2003).
59. Sharma, S.D., Mullenax, J., Araujo, F.G., Erlich, H.A. & Remington, J.S. Western blot analysis of the antigens of Toxoplasma gondii recognized by human IgM and IgG antibodies. J. Immunol. 131, 977-983 (1983).
60. Villegas, E.N. et al. Blockade of costimulation prevents infection-induced immunopathology in interleukin-10-deficient mice. Infect. Immun. 68, 2837-2844 (2000).